Sanofi and Regeneron's alirocumab tops Zetia, fueling PCSK9's blockbuster bluster

November 18, 2014 4:25 PM

1 0

Sanofi ($SNY) and Regeneron's ($REGN) alirocumab resoundingly beat out Merck's Zetia in helping statin-intolerant patients lower their bad cholesterol in a study, data that bolster the case for a new class of highly anticipated cardio drugs.

As Reuters reports, among the 360 patients in a Phase III study, those in the alirocumab arm reported a 45% LDL cholesterol reduction compared to just 14.6% for subjects taking Zetia. Furthermore, Sanofi and Regeneron's drug helped 42% of patients get lower their LDL to target levels while only 4% h...

Read more

To category page